Cancer-related mortality in Peru: Trends from 2003 to 2016

Jessica H. Zafra-Tanaka¹, Janeth Tenorio-Mucha¹, David Villarreal-Zegarra¹, Rodrigo Carrillo-Larco¹,²,³, Antonio Bernabe-Ortiz¹,⁴*

¹ CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, ² Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom, ³ Centro de Estudios de Población, Universidad Católica los Ángeles de Chimbote (ULADECH), Chimbote, Peru, ⁴ Universidad Científica del Sur, Lima, Peru

Abstract

Objectives

In the last decade, Latin American (LA) countries, like Peru, have undergone an epidemiological transition that has changed the pattern of oncological cases. Given that Peru’s oncological pattern could illustrate those of other LA countries, we aimed at determining trends and changes in cancer-related mortality by age and sex in Peru between 2003 and 2016.

Methods and results

A secondary data analysis using national deaths registries was conducted. Categories were created according to the 27 most frequent sites of presentation of cancer. We found that deaths attributed to cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p<0.001). According to the cancer site, stomach cancer (19.1%) and lung cancer (11.5%) were the most frequent causes of death overall. In childhood (0 to 14 years), the two most frequent fatal cancers were leukemia (54.6% for boys and 53.5% for girls) and brain and nervous system tumors (19.4% for boys and 20.3% for girls). For teenagers and young male adults (15–49 years), stomach cancer (18.1%) and brain cancer (17.4%) were the leading causes of death; in their female counterparts, cervix uteri (20.0%) and breast cancer (16.1%) were the most mortal cancers. In adults (≥50 years), stomach (20.9% for men and 18.6% for women) and lung (12.7% for men and 10.4% for women) were the leading contributors to the burden of cancer deaths.

Conclusions

Between the years 2003 and 2016, almost one fifth of deaths were attributed to cancer in Peru. Absolute and relative number of deaths due to cancer has increased in this period for both men and women; however, standardized mortality rates due to cancer have declined.
Introduction

Globally, cancer represents the second leading cause of death and was responsible for 8.8 million deaths in 2015 [1]. The largest cancer burden is in low- and middle-income countries (LMIC), where 60% of the total number of cases and 70% of the total number of deaths occur [2].

Several risk factors are associated with high cancer burden and mortality. Some of them can be non-modifiable such as age or sex [3, 4], while others are potentially modifiable such as nutrition and lifestyle behaviors [2]. The distribution of these factors plus the influence of demographic and epidemiological transitions have generated different patterns of cancer site presentations across countries and regions [5].

In the last decade, the oncological pattern has changed, and types of cancer once believed to be typical only of Western populations, such as colon or breast cancer, are now common in LMIC [2]. Two causes for these changes have been identified. First, behavioral risk factors for cancer such as unhealthy habits like smoking, fat and calorie-dense food consumption, and physical inactivity have increased in LMIC [6–8], and secondly, LMIC have experienced changes in population growth and ageing [9].

In the last decade, rates of oncological cases have increased in Peru. The oncological pattern in Peru, as well as in other countries in Latin America (LA), has changed from being mostly influenced by infectious agents to being affected by both infectious agents and lifestyles [5, 10]. Accordingly, between 2010 and 2012, the Lima surveillance system reported that largest mortality rates were due to prostate, stomach, and lung cancer for men; and stomach, cervix uteri and breast for women [11].

Prevention and early detection strategies should be tailored for a country or region [12]. Peru’s cancer mortality trends could provide an overview of the cancer transition in other LA countries, providing evidence to inform cancer control policies. Therefore, we aimed to determine the overall as well as age- and sex-specific trends in cancer-related mortality in Peru between 2003 and 2016 benefiting from nationally representative death registries.

Methods

Study design

A secondary data analysis using information of national deaths registries from 2003 to 2016 was conducted.

Data sources

National death registries are usually collected by the Peruvian Ministry of Health (MINSA). We analyzed registries from 2003 to 2016. MINSA collects mortality data at the national level using different sources: 1) all health establishment records, 2) the Registro Nacional de Identificación y Estado Civil (RENIÉC) and 3) the Ministerio Público [13–15].

Peruvian law dictates that when a person dies at any healthcare facility physicians are required to fill in a death certificate; these are compiled at the regional level and then sent to the MINSA central office. The health system in Peru is divided into Ministry of Health and Regional Government (MHRG), Social Security (EsSalud), Armed Forces and Police, and the Private sector; each sector offers differential treatment to their users. Information from MHRG are more likely to arrive at MINSA central office, and thus to be taken into account when managing mortality registries [16]. On the other hand, information from the remaining sectors might arrive late or not arrive at all, and may not be entirely reflected in national databases.
The Ministerio Público records and informs violent deaths: accidents, homicides or suspicious deaths (those not associated with previous medical conditions). However, data from Ministerio Público is underreported and do not always arrive at MINSA central office. Another source of vital record is RENIEC, which keeps records of vital events such as births and deaths nationally.

Given the multiple stages this information has to go through, there may be underreporting that needs to be taken into consideration when interpreting the results. Data quality control was performed excluding cases that presented inconsistent data (e.g. women with prostate cancer).

**Variables**

In order to assess trends in mortality due to cancer, death registries in which the underlying cause of death started with the letter C according to the ICD-10 coding system were considered. We did not consider cases of cancer-related to HIV since the incidence of HIV is not high in Peru and cancer due to HIV accounts for a small proportion of deaths of people living with HIV [17].

Cancers of interest herein analyzed were the 27 most frequent types of cancers according to the GLOBOCAN [18]. We used the ICD-10 coding (only the two first code numbers) to classify the different types. The categories are as follows: lip and oral cavity (C00 –C08), nasopharynx (C11), other pharynx (C09, C10, C12-C14), esophagus (C15), stomach (C16), colorectum (C18 –C21), liver (C22), gallbladder (C23 –C24), pancreas (C25), larynx (C32), lung (C33 –C34), melanoma of skin (C43), Kaposi sarcoma (C46), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64 –C66), bladder (C67), brain and nervous system (C70 –C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82 –C85 and C96), multiple myeloma (C88 and C90), and leukemia (C91 –C95).

For the analyses, we excluded the following codes because they do not specifically address one site of presentation and were not included in GLOBOCAN:[18] C17, C30, C31, C37, C38, C40, C44, C45, C47-C49, C51, C52, C55, C58-C60, C69, C74, C75. We also excluded all cancer with uncertain or non-specific sites of location such as C26, C38, C39, C41, C57, C63, C68, C76, C80, and C97 (See Fig 1). Finally, cancers with ICD-10 codes ranging from C77 to C79 were not considered in the analyses because these represent metastatic cancer and a higher level of detail in the diagnosis and in the ICD-10 codes are needed to identify the primary site. Thus, to avoid misclassification, we decided not to include them.

We also considered sex and age at death. Age was categorized as follows: childhood (0 to 14 years), teenagers and young adults (15 to 49 years), and adults (≥50 years). According to the WHO and England statistics, the most common cancers vary by sex in these age groups [19, 20].

**Statistical methods**

Absolute and relative frequencies were used to describe categorical variables, while central tendency and dispersion measures were used for quantitative variables. To compare and contrast the burden of deaths due to cancer in the previous years, we estimated mortality rates. We calculated the mortality rate dividing the number of deaths due to cancer by the expected population from the whole country for that year according to the National Institute of Statistics and Informatics (INEI in Spanish) [21]. These rates were age-standardized using the direct method and the global population 2000–2020 proposed by WHO [22]. Mann-Kendall test was used to assess time trends using cancer mortality age-standardized death rates. We also used a moving average technique using one lagged term, one forward term and the current observation to
create smoother curves. Graphs were elaborated using Microsoft Excel 2016 and statistical analyses were carried out using Stata v.14 (Stata Corp, College Station, TX, US).

**Ethics**
Data provided by MINSA is freely available and does not contain personal identifiers. Therefore, confidentiality and integrity were guaranteed.

**Results**

**Trends in mortality due to cancer**

Between 2003 and 2016, a total of 1,299,977 deaths occurred in Peru, of these, 244,471 (18.8%) were attributed to any cancer, and 209,813 (85.8% of all cancers) fall in one of the 27 categories used in this study (Fig 1). For those who died of cancer, the mean age at death was 65.4 years (SD = 18.5), and 52.9% were women.

The age-standardized mortality rates varied from 460.5 per 100,000 inhabitants in 2005 to 363.9 per 100,000 inhabitants in 2016, identifying a significant reduction over time (p < 0.001, p for moving average = 0.001). When analyzing deaths due to cancer, the age-standardized mortality rate varied from 90.9 per 100,000 inhabitants in 2005 to 66.0 per 100,000 inhabitants in 2016 (Table 1), identifying a significant reduction over time (p = 0.002, p for moving average < 0.001).

Mortality trends for cancer are shown in Fig 2A and 2B for women and men separately. Overall, deaths attributed to any cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p = 0.827, p for moving average = 0.029). These figures in women ranged from 13.1% to 20.8% (p = 0.080, p for moving average = 0.029), whereas in men these figures were 10.8% to

![Flowchart of selected type of cancers included in the study](https://doi.org/10.1371/journal.pone.0228867.g001)
For women, the age group that presented the highest proportion of deaths due to cancer was between 15–49 years; while for men, this group included those aged 50 years and above.

For women, the age-standardized mortality rate varied from 402.4 per 100,000 inhabitants in 2005 to 322.9 per 100,000 inhabitants in 2016, identifying a significant reduction in mortality trends over time ($p = 0.014$, $p$ for moving average $= 0.001$). When analyzing deaths due to cancer in women, the age-standardized mortality rate varied from 90.9 per 100,000 inhabitants in 2005 to 67.8 per 100,000 inhabitants in 2016 (Table 1), a significant reduction in trend over time ($p = 0.004$, $p$ for moving average $< 0.001$). For men, on the other hand, the age-standardized mortality rate varied from 527.7 per 100,000 inhabitants in 2005 to 408.6 per 100,000 inhabitants in 2016, identifying a significant reduction in trend over time ($p = 0.001$, $p$ for moving average $< 0.001$). When analyzing deaths due to cancer in men, the age-standardized mortality rate varied from 92.8 per 100,000 inhabitants in 2005 to 65.3 per 100,000 inhabitants in 2016 (Table 1), a significant reduction in trend over time ($p = 0.003$, $p$ for moving average $< 0.001$).

### Trends according to site of presentation
Stomach cancer (18.4%) and lung cancer (10.7%) were the most frequent causes of death overall (Appendix 1) across study years. Additionally, to depict variations across time, the ranking of the sex- and age-stratified top 10 cancers in 2003, 2009 and 2016 are shown in Appendix 2.

For teenagers and young adults between 2003 and 2016, stomach cancer ranked between the third and fourth place for women and first for men. In men and women $\geq 50$ years, stomach cancer was the leading cause of cancer deaths in all years except in 2016, when prostate cancer was the leading cause of cancer death in men. Nevertheless, the proportion of deaths attributed to stomach cancer across time (2003–2016) has declined for those $\geq 50$ years; from

| Year | Age-standardized mortality rate per 100,000 hab. in Peru (Global population 2000–2020) | Age-standardized mortality rate due to cancer per 100,000 hab. in Peru (Global population 2000–2020) | Age-standardized mortality rate due to other causes per 100,000 hab. in Peru (Global population 2000–2020) | Age-standardized mortality rate due to cancer per 100,000 hab. in Peru (Global population 2000–2020) for women | Age-standardized mortality rate due to other causes per 100,000 hab. in Peru (Global population 2000–2020) for women | Age-standardized mortality rate due to cancer per 100,000 hab. in Peru (Global population 2000–2020) for men | Age-standardized mortality rate due to other causes per 100,000 hab. in Peru (Global population 2000–2020) for men |
|------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| 2005 | 460.5 90.9 369.7 402.4 90.9 311.4 527.7 92.8 434.9 |
| 2006 | 415.8 82.3 333.4 361.7 79.1 282.6 478.2 87.9 390.3 |
| 2007 | 429.8 83.5 346.4 373.2 82.8 290.4 495.6 85.9 409.7 |
| 2008 | 433.7 86.3 347.4 377.3 84.7 292.6 499.3 90.1 409.3 |
| 2009 | 440.2 84.8 355.5 382.3 83.3 299.0 507.2 88.1 419.0 |
| 2010 | 445.6 83.9 361.7 385.4 82.4 303.0 515.8 87.6 428.2 |
| 2011 | 421.9 80.2 341.7 376.8 83.2 293.7 480.2 81.1 399.1 |
| 2012 | 413.9 78.9 335.0 356.2 77.4 278.8 481.4 82.4 399.0 |
| 2013 | 403.8 76.4 327.4 349.7 75.0 274.7 467.1 80.1 387.0 |
| 2014 | 382.5 77.7 304.8 329.0 75.7 253.4 445.1 81.7 363.4 |
| 2015 | 369.8 74.6 295.2 318.2 72.4 245.7 430.2 78.9 351.3 |
| 2016 | 363.9 66.0 297.9 322.9 67.8 255.1 408.6 65.3 343.3 |

https://doi.org/10.1371/journal.pone.0228867.t001
24.4% to 16.44% among women (p = 0.006, p for moving average < 0.001), and from 25.7% to 21.8% among men (p = 0.038, p for moving average = 0.004).

Lung cancer was another leading cause of cancer death throughout the study period, especially among those ≥50 years. Between 2003 and 2009, the proportion of cancer deaths due to lung cancer increased from 8.7% to 10.6% for women and then level off through 2016.

**Trends according to site of presentation, age, and sex**

Fig 3A, 3B and 3C display the percentages of the three leading causes of cancer deaths according to sex and age group. These figures also show their variations between 2003 and 2016. In childhood (0 to 14 years), the two leading causes of death were leukemia (55.6% for boys and 53.5% for girls) and brain and nervous system cancers (19.4% for boys and 20.3% for girls).
For boys, the third most common cause of death was non-Hodgkin lymphoma (7.7%), while for girls it was liver cancer (5.1%).

For teenagers and young adults (15–49 years), stomach cancer (18.1%), brain cancer (17.4%), and non-Hodgkin lymphoma (11.5%) were the three leading causes of cancer death in men; while cervix uteri cancer (20.0%), breast cancer (16.1%), and stomach cancer (12.8%) were major contributors to cancer mortality in women.

In adults ≥50 years, stomach (20.9% for men and 18.6% for women) and lung (12.7% for men and 10.4% for women) were the leading contributors to the burden of cancer deaths. In addition, prostate and cervix uteri represented 21.0% and 10.1% of the deaths due to cancer in men and women, respectively.

Discussion

Between 2003 and 2016 in Peru, almost one-fifth of deaths were attributed to cancer. Although age-standardized rates declined through these years, the absolute number of deaths due to cancer has increased in this period for both men and women, compared to deaths from other causes. The distribution of the neoplasm’s site presentation varied according to age and sex; however, the most important sites were stomach and lung for adults in general, and leukemia in children.

Cancer mortality trends

Globally, deaths attributed to cancer have increased from 13.3% in the year 2000 to 15.5% in 2015 [19]. This can be explained by aging populations, lifestyle-related risk factors and a
decrease in the proportion of deaths attributed to infectious diseases [19]. Our study found that one-fifth of deaths were attributed to cancer. WHO estimates of country-level causes of death, found a global estimate of 15.5% of deaths due to cancer, and a 20% estimate for upper-middle-income countries [19]. Given the current economic transition that LMIC undergo, lifestyle-related factors like, decreasing physical activity, increasing sedentary behaviors (e.g., due to changes in transportation), smoking and poor dietary habits are becoming more common in LMIC [5]. Given that these factors are present in Peru [23], it is not a surprise that cancer represents a significant cause of death in this country.

Overall, the age-standardized rate of cancer mortality seemed to have declined in Peru for both men and women from year 2005 to year 2016. This decline has also been found by a study from Our World in Data, that quantified the reduction of age-standardized rate of cancer mortality in Peru of 14.1%, which is higher than the reduction worldwide (7.2%) or the reduction in Andean Latin America (11.1%) for that period of time [24]. This may be explained by actions taken by the government to increase preventative and treatment services. For example, neoplastic care services have been decentralized and replaced with three regional institutes; increasing access to treatment. The government has also implemented new health strategies focused on cancer prevention, early detection, diagnosis, and proper treatment. Specifically, the Plan Esperanza [25] was implemented in 2012 with the objective to reduce cancer mortality and morbidity through better access to oncological care, promotion of healthy activities, prevention, and early diagnosis [25, 26], and it’s focused on breast, cervix uteri, colon, stomach, prostate, leukemia and lymphoma. Strategies implemented in HIC have demonstrated that prevention and early detection reduce cancer burden, however replicating these strategies in LMIC deal with healthcare infrastructure, lack of cancer awareness, insufficient funding, competing health priorities, and limited human resources [12].

One additional thing to note is that our study found a much higher reduction compared to that of the Our World in Data study; 27.4% versus 14.1%. This might be due to the types of cancer considered in the analysis; we have considered the 27 most frequent types of cancers and the data used by that study includes all cancer types [24]. A bigger reduction in the most frequent cancer is expected as public health interventions would be focused on those types of cancers.

When interpreting standardized-mortality rates is not possible to evaluate the influence of the aging of the population on mortality rates because of the age adjustment performed in the data. This is of great importance given that mortality is higher in older people, and this population is increasing in Peru. Thus, in 2005 people over 50 year represented only 14.8% of the entire population but in span of ten years this population increased to 18.3%. It is logical that when analyzing the proportion of deaths due to cancer, it has increased throughout the years for both men and women.

**Trends according to site of presentation, age, and sex**

**Childhood (0 to 14 years).** Leukemia was the most important cause of cancer deaths during childhood, followed by brain and nervous system cancer, as shown in different countries in previous studies [18, 27]. These types of cancers are more lethal in LMIC compared to high-income countries (HIC) [18]. Possible explanations are late diagnosis and abandonment of therapy. According to data of the CONCORD program, the inequities between HIC and LMIC could be reduced by improving the access to health care and providing appropriate treatment [28].

**Teenagers and young adults (15 to 49 years).** Stomach, leukemia, and brain and nervous system cancer are the leading causes of cancer death among men between 15 and 49 years. In
teenagers and young women; cervix uteri, breast and stomach cancer are the leading causes of
death due to cancer. It is important to note that, within this age group, mortality due to cancer
is much higher in women (around 20% in the studied years) compared to men (around 10% in
the studied years), because of cervix uteri and breast cancer.

The cervix uteri cancer is the fourth most common cause of cancer death in women world-
wide [2], 70% of the world’s burden is in LMIC [2]. Our data ranked it as the leading cause
of cancer death in women of this age. The low rates of survival could be attributed to late detec-
tion and lack of access to treatment. Recently, Peru has initiated a vaccination program against
HPV in girls attending school [11, 29]. However, it has been only a few years since this pro-
gram started, so the impact of the program cannot be seen yet.

Breast cancer is the most frequent cancer in women worldwide,[2] the incidence in LMIC
doubles that of HIC [2]. In Peru, it is the most frequent cancer in women and our results
ranked it as the second cause of cancer death in adult women. In LA, deaths are associated
with late detection and treatment [30], which could also be the case in our country. For exam-
ple, the proportion of in-situ breast cancer in LA countries rank between 4 to 6%, while for
North America it is 17.3%, and the 5-year survival rates from 2010 to 2014 varied between
50.2% and 89.8% in LA, and from 88.2% to 90.2% in North America [31].

Stomach cancer is the third cause of death worldwide with high mortality rates seen in Cen-
tral and South America [18]. In Peru, it represents the leading cancer cause of death in adults,
and is possibly explained by Helicobacter pylori infections, dietary and lifestyle factors, and
 genetic factors [32]. There are reasons to believe that the trend of deaths from gastric cancer
could be increasing in Peru because of waterborne transmission of H. pylori [32] due to poor
hygiene, and antibiotic resistance to standard therapy for this bacteria [33–35]. Despite this,
according to our analysis, the proportion of deaths due to gastric cancer has declined between
2003 and 2016.

Adults (≥50 years). In adult men, stomach, prostate and lung cancer were the leading
causes of death, whereas, in adult women, these cancers were stomach and lung cancer, fol-
lowed by cervical cancer.

Lung cancer represents the second leading cause of death due to cancer. Worldwide, lung
cancer is responsible for nearly one-fifth of deaths due to cancer according to GLOBOCAN
[18]. Women have some advantages compared to men regarding lung cancer diagnosis and
treatment: women are more likely to be diagnosed with a localized disease [36], and the
response to chemotherapy is better in women [37, 38]. In spite of these advantages, lung cancer
still poses a significant burden of mortality in women. This may be due to the difficulties in
early detection and the lack of access to proper care that affects both sexes. Additionally, there
are regional variations, which may be due to smoking and environmental exposures [10]. Even
though the prevalence of daily smoking in Peru is still low (3.3%) [39, 40], it is still necessary to
implement policies in order to further reduce tobacco use. Additionally, it is known that
indoor smoke emissions are also associated with lung cancer [41]. Around the 20% of the
Peruvian population still use biomass to cook, especially in rural areas [42], and if we consider
poor living conditions, inefficient health and educational conditions—common in those areas—it represents a significant public health problem. Therefore, it is vital to promote strategies to
improve cooking conditions in vulnerable populations.

Prostate cancer is the second leading cancer and the fifth leading cause of death from cancer
in men worldwide. Among nations with high Human Development Index (HDI), prostate
cancer incidence rates have increased due to the implementation of screening tests, whereas
mortality rates have declined because of early detection and well-timed treatment [43–45].
Unfortunately, in our country, late-stage diagnosis in older men continues to be a problem,
thereby increasing the lethality of these cancers.
**Limitations and strengths**

Our study analyzed cancer mortality trends over more than a decade in Peru (2003–2016), and provides a view of how cancer mortality trends have changed over time. These trends are important not only to facilitate planning resource allocation but also to assess the impact of public health interventions.

Our study has some limitations, the most important being the lack of high-quality data to assess cancer mortality trends due to sub-registry errors in identification and codification of causes of deaths. When assessing the civil registration and vital statistics system in Peru, one study found that its performance was poor (<0.70) as it was around 57.3 between years 2005–2009, and around 49.9 between years 2010–2012 [46]. This might be due to the partitioned health registries that prevent the MINSA from getting all information in a timely manner [47], and registries from MHRG are more likely to have been reported and therefore are better represented than those from EsSalud or Armed Forces. Given that any Peruvian patient, independent of their type of health insurance coverage, can get health care in MHRG establishments; it is not possible for us to assess the level of under-registry from each sector.

Another limitation is the lack of measurement of certain variables that could help us to better understand our results. For example, some variables might be associated with access to health services such as socioeconomic status or whether each person had health insurance or not. Nonetheless, we feel that our study sheds important light on a significant public health concern in Peru: nationally representative cancer mortality trends.

**Conclusions**

Between the years 2003 and 2016 in Peru, almost one-fifth of deaths were attributed to cancer. Both absolute and relative number of deaths attributed to cancer has increased in this period of time for both men and women; however, standardized mortality rates have declined. This could be a reflection of the health systems response to cancer care. However, cancer programs should be prepared for the increasing number of cases of cancer. Moreover, prevention, early detection and proper access to treatment strategies must consider differences in the mortality distribution of sites of neoplasm by age and sex.

**Supporting information**

S1 Appendix. (DOCX)

S2 Appendix. (DOCX)

S1 Table. Cancer deaths by sex and types of cancer in Peruvian population, 2003–2016. (DOCX)

S2 Table. Ranking of the 10 leading types of cancers in 2003, 2009 and 2016, by sex and age group. (DOCX)

**Author Contributions**

**Conceptualization:** Jessica H. Zafra-Tanaka, Janeth Tenorio-Mucha, David Villarreal-Zegarra, Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.
Data curation: Jessica H. Zafra-Tanaka, Janeth Tenorio-Mucha, David Villarreal-Zegarra, Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.

Formal analysis: Jessica H. Zafra-Tanaka, Janeth Tenorio-Mucha, David Villarreal-Zegarra, Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.

Funding acquisition: Rodrigo Carrillo-Larco.

Methodology: David Villarreal-Zegarra, Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.

Software: Antonio Bernabe-Ortiz.

Supervision: Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.

Visualization: Antonio Bernabe-Ortiz.

Writing – original draft: Jessica H. Zafra-Tanaka, Janeth Tenorio-Mucha.

Writing – review & editing: David Villarreal-Zegarra, Rodrigo Carrillo-Larco, Antonio Bernabe-Ortiz.

References
1. World Health Organization. Cancer Fact sheet 2017. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
2. Stewart B, Wild CP. World cancer report 2014. France: World Health Organization; 2014.
3. Han R, Zheng R, Zhang S, Wu M, Chen W. [Trend analyses on the differences of lung cancer incidence between gender, area and average age in China during 1989–2008]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2013; 16(9):445–51. Epub 2013/09/17. https://doi.org/10.3779/j.issn.1009-3419.2013.09.02 PMID: 24034990.
4. Hussein S, Sattunwar S, Van der Kwast T. Young-age prostate cancer. Journal of clinical pathology. 2015; 68(7):511–5. Epub 2015/04/04. https://doi.org/10.1136/jclinpath-2015-202993 PMID: 25837493.
5. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016; 25(1):16–27.
6. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. The Lancet Oncology. 2012; 13(8):790–801. Epub 2012/06/05. https://doi.org/10.1016/S1470-2045(12)70211-5 PMID: 22658655.
7. Bray F, Moller B. Predicting the future burden of cancer. Nature reviews Cancer. 2006; 6(1):63–74. Epub 2005/12/24. https://doi.org/10.1038/nrc1781 PMID: 16372017.
8. Arnold M, Sierra MS, Lavransanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016. https://doi.org/10.1136/gutjnl-2015-310912 PMID: 26818619.
9. World Health Organization. Global Health Observatory (GHO) data—Life expectancy 2018 [14th November, 2018]. Available from: http://www.who.int/gho/mortality_burden_disease/life_tables/situation_trends/en/.
10. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010; 19(8):1893–907. Epub 2010/07/22. https://doi.org/10.1158/1055-9965.epi-10-0437 PMID: 20647400.
11. Piñeros M, Ramos W, Antoni S, Abriata G, Medina LE, Miranda JJ, et al. Cancer patterns, trends, and transitions in Peru: a regional perspective. The Lancet Oncology. 2017; 18(10):e573–e86. https://doi.org/10.1016/S1470-2045(17)30377-7 PMID: 28971824.
12. Ilbawi AM, Anderson BO. Cancer in global health: how do prevention and early detection strategies relate? Science translational medicine. 2015; 7(278):278cm1. Epub 2015/03/13. https://doi.org/10.1126/scitranslmed.3008853 PMID: 25761886.
13. Instituto Nacional de Estadística e Informática. Sistema Estadístico Nacional 2018 [9 March, 2018]. Available from: https://www.inei.gob.pe/.
14. Registro Nacional de Identificación y Estado Civil. ¿Quiénes somos? 2018 [9 March, 2018]. Available from: https://www.reniec.gob.pe/portal/institucional.html.
15. Ministerio de Salud. Carga de enfermedad en el Perú: Estimación de los años de vida saludables perdidos 2012. Lima, Perú 2014.

16. Vargas-Herrera J, Ruiz KP, Nuñez GG, Ohno JM, Pérez-Lu JE, Huarcaya WV, et al. Resultados preliminares del fortalecimiento del sistema informático nacional de defunciones. Revista Peruana de Medicina Experimental y Salud Pública. 2018; 35(3):505–14. https://doi.org/10.17843/rpmsnp.2018.353.3913 PMID: 30517488

17. Centro Nacional de Epidemiología. Prevención y Control de Enfermedades. Situación epidemiológica del VIH-Sida en el Perú. Boletín mensual—Octubre 2017. Lima, Perú: Ministerio de Salud, 2017.

18. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebello M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136(5):e359–e86. https://doi.org/10.1002/ijc.29210 PMID: 25220842

19. World Health Organization. Global Health Estimates 2015 summary. Global Deaths by cause, age and sex, by World Bank income group, 2000–2015: World Health Organization; 2016. Available from: http://www.who.int/healthinfo/global_burden_disease/en/.

20. Office for National Statistics. Cancer Registration Statistics, England: 2015. Cancer diagnoses and age-standardised incidence rates for all cancer sites by age, sex and region. 2017.

21. Instituto Nacional de Estadística e Informática. Estimaciones y Proyecciones de Población. Población total al 30 de junio, por grupos quinquenales de edad, según departamento, provincia y distrito Perú [cited 2018 March 22]. Available from: https://www.inei.gob.pe/media/MenuRecursivo/indices_tempaticos/cuadro001_1.xls.

22. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new method and its application. World Health Organization: Geneva; 2001.

23. Benziger CP, Zavala-Loayza JA, Bernabe-Ortiz A, Gilman RH, Checkley W, Smeeth L, et al. Low prevalence of ideal cardiovascular health in Peru. Heart (British Cardiac Society). 2018. Epub 2018/01/13. https://doi.org/10.1136/heartjnl-2017-312255 PMID: 29326111.

24. Our World in Data. Cancer: Comparing absolute deaths, the death rate, and the age-standardized death rate 2018 [11th December, 2019]. Available from: https://ourworldindata.org/cancer#is-the-mortality-of-cancer-on-the-rise.

25. Vidaurre T, Santos C, Gomez H, Sarria G, Amorin E, Lopez M, et al. The implementation of the Plan Esperanza and response to the imPACT Review. The Lancet Oncology. 2017; 18(10):e595–e606. Epub 2017/10/04. https://doi.org/10.1016/S1470-2045(17)30598-3 PMID: 28971826.

26. Salazar MR, Regalado-Rafael R, Narvaro JM, Montanez DM, Abugattas JE, Vidaurre T. [The role of the National Institute of Neoplastic Diseases in the control of cancer in Peru]. Rev Peru Med Exp Salud Publica. 2013; 30(1):105–12. Epub 2013/04/25. https://doi.org/10.1590/s1726-46342013000100020 PMID: 23612822.

27. Ostrom QT, Gittleman LJ, Berezin E, Chen Z, Ross ME, Heros RC, et al. Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro-oncology. 2015; 17 Suppl 4:i–vi. Epub 2015/10/30. https://doi.org/10.1093/neocon/vnv008 PMID: 26512114; PubMed Central PMCID: PMC4623240.

28. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The Lancet Oncology. 2008; 9(8):730–56. Epub 2008/07/22. https://doi.org/10.1016/S1470-2045(08)70179-7 PMID: 18639491.

29. Goldie SJ, Levin C, Mosquesia-Lovon NR, Ortentahal J, Kim J, O’Shea M, et al. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Revista panamericana de salud publica = Pan American journal of public health. 2012; 32(6):426–34. Epub 2013/02/02. PMID: 23370186.

30. Lozano-Ascencio R, Gomez-Dantes H, Lewis S, Torres-Sanchez L, Lopez-Carrillo L. Tendencias de la mortalidad de cáncer de mama en America Latina y el Caribe. Salud publica de Mexico. 2009; 51 Suppl 2:s147–56. Epub 2010/01/09. https://doi.org/10.1590/s0036-36342009000800004 PMID: 19967269.

31. Allemanni C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018; 391(10125):1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3 PMID: 29390269.

32. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Medical Journal. 2014; 55(12):621–8. https://doi.org/10.11622/smedj.2014174 PMC4291986. PMID: 25630323

33. Ghoslosiu R, Leylabadio HE, Asi YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World Journal of Methodology. 2015; 5(3):164–74. https://doi.org/10.5662/wjm.v5.i3.164 PMC4572030. PMID: 26413490
34. Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, et al. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infection and Drug Resistance. 2017; 10:85–90. https://doi.org/10.2147/S123798 PMCS5354526. PMID: 28331349
35. Camargo MC, Garcia A, Riquelme A, Otero W, Camargo CA, Hernandez-Garcia T, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. The American journal of gastroenterology. 2014; 109(4):485–95. Epub 2014/03/05. https://doi.org/10.1038/ajg.2014.24 PMID: 24589670; PubMed Central PMCID: PMC4268683.
36. Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer: Targets and Therapy. 2012; 3:79–89. https://doi.org/10.2147/LCTT.S37319 PMCS312492. PMID: 28210127
37. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006; 1(5):441–6. Epub 2007/04/06. PMID: 17409897.
38. Schiller JH, Harrington D, Belani CP, Langer A, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine. 2002; 346(2):92–8. Epub 2002/01/11. https://doi.org/10.1056/NEJMoa011954 PMID: 11784875.
39. Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diatte GB, Miele CH, et al. Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respiratory research. 2015; 16:40. Epub 2015/04/19. https://doi.org/10.1186/s12931-015-0198-2 PMID: 25889777; PubMed Central PMCID: PMC438577.
40. Morgan BW, Lefthiet KM, Romero KM, Gilman RH, Bernabe-Ortiz A, Miranda JJ, et al. Low cigarette smoking prevalence in peri-urban Peru: results from a population-based study of tobacco use by self-report and urine cotinine. Tobacco induced diseases. 2017; 15:32. Epub 2017/07/25. https://doi.org/10.1186/s12971-017-0137-8 PMID: 28736513; PubMed Central PMCID: PMC5521105.
41. Hosgood HD 3rd, Boffetta P, Greenland S, Lee YC, McLaughlin J, Seow A, et al. In-home coal and wood use and lung cancer risk: a pooled analysis of the International Lung Cancer Consortium. Environmental health perspectives. 2010; 118(12):1743–7. Epub 2010/09/18. https://doi.org/10.1289/ehp. 1002217 PMID: 20846923; PubMed Central PMCID: PMC3002194.
42. Instituto Nacional de Estadística e Informática. El 80,7% de los hogares utilizó gas para cocinar 2015. Available from: https://www.inei.gob.pe/prensa/noticias/el-807-de-los-hogares-utilizo-gas-para-cocinar-8610/.
43. Etzioni R, Penson DF, Legler JM, Di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute. 2002; 94(13):981–90. Epub 2002/07/04. https://doi.org/10.1093/jnci/94.13. 981 PMID: 12096083.
44. Hassanpour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhid F, Jamehshorani S, Salehinia H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate international. 2016; 4(3):118–24. Epub 2016/10/01. https://doi.org/10.1016/j.pimi.2016.07.001 PMID: 27689070; PubMed Central PMCID: PMC5031898.
45. Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Jama. 2018; 319(9):883–95. Epub 2018/03/07. https://doi.org/10.1001/jama.2018.0154 PMID: 29509864.
46. Mikkelsen L, Phillips DE, AbouZahr C, Setel PW, De Savigny D, Loozma R, et al. A global assessment of civil registration and vital statistics systems: monitoring data quality and progress. The Lancet. 2015; 386(10001):1395–406.
47. OECD Reviews of Health Systems. Monitoring Health System Performance in Peru: Data and Statistics. Paris: OECD Reviews of Health Systems; 2017.